Greenleaf Trust Cuts Position in Pfizer Inc. $PFE

Key Points

• Greenleaf Trust reduced its stake in Pfizer by 11.0%, owning 224,828 shares after selling 27,921 shares during the second quarter.
• Notably, several institutional investors have also adjusted their positions in Pfizer, with institutional ownership at 68.36%.
• Pfizer recently reported $0.78 earnings per share for the quarter, surpassing analysts' expectations, and set FY 2025 guidance at 2.900-3.100 EPS.

Greenleaf Trust reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 224,828 shares of the biopharmaceutical company's stock after selling 27,921 shares during the quarter. Greenleaf Trust's holdings in Pfizer were worth $5,450,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. acquired a new stake in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new position in Pfizer in the first quarter worth $28,000. Horizon Financial Services LLC acquired a new position in shares of Pfizer during the first quarter worth $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at $35,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on PFE shares. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Price Performance

Shares of PFE opened at $23.84 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a market cap of $135.54 billion, a P/E ratio of 12.68, a PEG ratio of 0.77 and a beta of 0.55. The firm's 50 day moving average price is $24.54 and its 200 day moving average price is $24.11.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.